People Who Have Prostate Cancer Cannot Have Testosterone
People Who Have Prostate Cancer Cannot Have Testosterone
Individuals with prostate cancer are typically advised against testosterone therapy as part of gender affirming care due to potential risks associated with hormone-sensitive tumors. Testosterone, a primary component of masculinizing hormone therapy, can stimulate the growth and proliferation of prostate cancer cells, potentially accelerating tumor growth or increasing the risk of cancer recurrence. Therefore, testosterone therapy is contraindicated in individuals with a history of prostate cancer or those currently undergoing treatment for the disease.
Embarking on gender-affirming care while undergoing treatment for cancer presents unique challenges and considerations. This situation requires a delicate balance between respecting personal gender identity goals and addressing the medical ...
Breast cancer The lifetime risk of breast cancer for cis women is approximately 12%, while the lifetime risk for cis men is approximately 0.1% (Sonnenblick et al., 2018). Research has shown that the lifetime risk of breast cancer for trans women on ...
Individuals who have previously had breast cancer should not use estrogen as part of gender-affirming care due to the potential risks associated with hormone-sensitive cancers. Estrogen therapy, a key component of feminizing hormone therapy, can ...
Individuals who are pregnant or breastfeeding are advised against testosterone therapy as part of gender affirming care due to potential risks to both the individual and the developing fetus or breastfeeding infant. Testosterone, a key component of ...
Erythrocytosis refers to thickening of the blood due to increased red blood cell production. The thickness of the blood is measured with a blood test for haematocrit, which is an estimated percentage by volume of red blood cells in the blood. The ...
